Covid19 Clinical Trial
Official title:
Evaluation of Respiratory Muscle Strength and Pulmonary Functions in Volleyball Players Suffering From Covid-19
| NCT number | NCT04789512 |
| Other study ID # | 2021-189 |
| Secondary ID | |
| Status | Completed |
| Phase | |
| First received | |
| Last updated | |
| Start date | March 1, 2021 |
| Est. completion date | March 29, 2021 |
| Verified date | March 2021 |
| Source | Gazi University |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Observational |
In literature, there is no data evaluating respiratory functions in volleyball players during Covid-19 pandemic. The aim of this study is to evaluate and compared pulmonary functions, respiratory muscle strength, body compositions and performance situations perceptions in female volleyball players with Covid-19 and non-Covid-19.
| Status | Completed |
| Enrollment | 42 |
| Est. completion date | March 29, 2021 |
| Est. primary completion date | March 26, 2021 |
| Accepts healthy volunteers | Accepts Healthy Volunteers |
| Gender | Female |
| Age group | 15 Years to 35 Years |
| Eligibility | Inclusion Criteria: - having passed at least 30 days after the Polymerase Chain Reaction (PCR) test turned negative - willing to participate in the study Exclusion Criteria: - having a history of chronic lung disease - unwilling to participate in the study |
| Country | Name | City | State |
|---|---|---|---|
| Turkey | Gazi University | Ankara | Çankaya |
| Lead Sponsor | Collaborator |
|---|---|
| Gazi University |
Turkey,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Respiratory muscle strength | Maximal inspiratory and expiratory muscle strength will be evaluated using mouth pressure device. | 10 minute | |
| Secondary | FEV1 | Pulmonary function tests will be performed using a spirometry according to the American Thoracic Society and European Respiratory Society criteria. FEV1 will be evaluated. The percentage of predicted value <70% will be expressed as abnormal. | 5 minute | |
| Secondary | FVC | Pulmonary function tests will be performed using a spirometry according to the American Thoracic Society and European Respiratory Society criteria. FVC will be evaluated. The percentage of predicted value <70% will be expressed as abnormal | 5 minute | |
| Secondary | FEV1/FVC | Pulmonary function tests will be performed using a spirometry according to the American Thoracic Society and European Respiratory Society criteria. FEV1/FVC will be evaluated. | 5 minute | |
| Secondary | PEF | Pulmonary function tests will be performed using a spirometry according to the American Thoracic Society and European Respiratory Society criteria. PEF will be evaluated. The percentage of predicted value <70% will be expressed as abnormal. | 5 minute | |
| Secondary | FEF2575 | Pulmonary function tests will be performed using a spirometry according to the American Thoracic Society and European Respiratory Society criteria. FEF2575 will be evaluated. The percentage of predicted value <50% will be expressed as abnormal. | 5 minute | |
| Secondary | Fat mass | Fat mass will be evaluated using TANITA bioelectrical impedance analysis. | 2 minute | |
| Secondary | Fat mass percent | Fat mass percent will be evaluated using TANITA bioelectrical impedance analysis. | 2 minute | |
| Secondary | Fat-free mass | Fat-free mass will be evaluated using TANITA bioelectrical impedance analysis. | 2 minute | |
| Secondary | Body mass index | Body mass index will be evaluated using TANITA bioelectrical impedance analysis. | 2 minute | |
| Secondary | Predicted muscle mass | Predicted muscle mass will be evaluated using TANITA bioelectrical impedance analysis. | 2 minute | |
| Secondary | Symptom severity perceptions | Symptom severity perceptions will be evaluated Numeric Rating Scale.The severity of symptoms perceptions related to Covid are scored 0-10 point. Higher scores indicate higher severity of symptoms. | 1 minute | |
| Secondary | Performance situations perceptions | Performance situations perceptions will be evaluated Numeric Rating Scale. Performance situations perceptions of all players are also scored 0-10 point. Higher scores indicate greater performance. | 1 minute |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT05047692 -
Safety and Immunogenicity Study of AdCLD-CoV19-1: A COVID-19 Preventive Vaccine in Healthy Volunteers
|
Phase 1 | |
| Recruiting |
NCT04395768 -
International ALLIANCE Study of Therapies to Prevent Progression of COVID-19
|
Phase 2 | |
| Completed |
NCT04508777 -
COVID SAFE: COVID-19 Screening Assessment for Exposure
|
||
| Terminated |
NCT04555096 -
A Trial of GC4419 in Patients With Critical Illness Due to COVID-19
|
Phase 2 | |
| Completed |
NCT04506268 -
COVID-19 SAFE Enrollment
|
N/A | |
| Completed |
NCT04961541 -
Evaluation of the Safety and Immunogenicity of Influenza and COVID-19 Combination Vaccine
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT04546737 -
Study of Morphological, Spectral and Metabolic Manifestations of Neurological Complications in Covid-19 Patients
|
N/A | |
| Completed |
NCT04494646 -
BARCONA: A Study of Effects of Bardoxolone Methyl in Participants With SARS-Corona Virus-2 (COVID-19)
|
Phase 2 | |
| Terminated |
NCT04542993 -
Can SARS-CoV-2 Viral Load and COVID-19 Disease Severity be Reduced by Resveratrol-assisted Zinc Therapy
|
Phase 2 | |
| Not yet recruiting |
NCT04543006 -
Persistence of Neutralizing Antibodies 6 and 12 Months After a Covid-19
|
N/A | |
| Completed |
NCT04532294 -
Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2/COVID-19) Neutralizing Antibody in Healthy Participants
|
Phase 1 | |
| Terminated |
NCT04581915 -
PHRU CoV01 A Trial of Triazavirin (TZV) for the Treatment of Mild-moderate COVID-19
|
Phase 2/Phase 3 | |
| Not yet recruiting |
NCT04527211 -
Effectiveness and Safety of Ivermectin for the Prevention of Covid-19 Infection in Colombian Health Personnel
|
Phase 3 | |
| Completed |
NCT04537663 -
Prevention Of Respiratory Tract Infection And Covid-19 Through BCG Vaccination In Vulnerable Older Adults
|
Phase 4 | |
| Completed |
NCT04507867 -
Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III
|
N/A | |
| Completed |
NCT04387292 -
Ocular Sequelae of Patients Hospitalized for Respiratory Failure During the COVID-19 Epidemic
|
N/A | |
| Not yet recruiting |
NCT05038449 -
Study to Evaluate the Efficacy and Safety of Colchicine Tablets in Patients With COVID-19
|
N/A | |
| Completed |
NCT04979858 -
Reducing Spread of COVID-19 in a University Community Setting: Role of a Low-Cost Reusable Form-Fitting Fabric Mask
|
N/A | |
| Completed |
NCT04610502 -
Efficacy and Safety of Two Hyperimmune Equine Anti Sars-CoV-2 Serum in COVID-19 Patients
|
Phase 2 | |
| Active, not recruiting |
NCT06042855 -
ACTIV-6: COVID-19 Study of Repurposed Medications - Arm G (Metformin)
|
Phase 3 |